From oral biologics to next-generation RNA therapies, companies are investing heavily in platforms that redefine how medicines are delivered and where they act.

Korsana Biosciences raised $175 million to develop next-generation Alzheimer’s antibodies. Its lead candidate uses transferrin receptor targeting to cross the blood-brain barrier. The company plans to enter clinical trials in 2027. Several competitors are pursuing similar delivery strategies.